Academic medical centers and cooperative clinical trial networks
Key Highlights
Pioneered research and clinical application of Minimal Residual Disease (MRD) in acute leukemias and lymphomas.
Led pivotal multi-center clinical trials establishing rituximab and other antibody-based therapies as standards of care in lymphoma.
Contributed to advancements in hematopoietic cell transplantation and innovative lymphoma therapies including antibody–drug conjugates.
Guideline-Based Recommendations
Diagnosis
Utilize MRD testing to assess residual disease in acute myeloid and lymphoblastic leukemias.
Incorporate MRD assessment in clinical decision-making for lymphoma management.
Management
Employ hematopoietic cell transplantation as a treatment modality in lymphomas.
Use antibody therapies such as rituximab, ofatumumab, 90Y-ibritumomab tiuxetan, and brentuximab vedotin in appropriate lymphoma subtypes.
Consider cost-effectiveness and patient access when selecting therapeutic strategies.
Monitoring & Follow-up
Monitor MRD levels to guide treatment response and detect relapse.
Implement e-health programs to support patient well-being and manage cancer-related fatigue.
Risks
Be aware of limitations in MRD testing including non-uniform distribution of leukemia cells.
Consider potential adverse effects and access issues related to expensive antibody-based therapies.
Patient & Prescribing Data
Patients with advanced follicular lymphoma, Hodgkin disease, and acute leukemias undergoing transplantation or antibody therapy.
Rituximab established as standard-of-care; early international studies demonstrated efficacy of ofatumumab, 90Y-ibritumomab tiuxetan, and brentuximab vedotin; MRD testing informs treatment adjustments.
Clinical Best Practices
Integrate MRD testing into routine diagnostic and monitoring protocols for hematologic malignancies.
Participate in cooperative group clinical trials to advance lymphoma therapies.
Address patient quality of life through supportive care initiatives including e-health fatigue management.
Balance innovative therapy benefits with considerations of cost-effectiveness and equitable drug access.
